Popular Articles
Burdock Root

Aegerion Pharmaceuticals Announces Final Lomitapide (AEGR-733) Phase II Data
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, announced final data from three separate Phase II trials involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein inhibitor (MTP-I) small molecule drug. The final data was recently presented at the American Diabetes Association"s "69th Scientific Sessions" in New Orleans, LA on June 7, 2009 and the International Symposium on Atherosclerosis (ISA) in Boston, MA on June 15, 2009.
generic viagra online
UPCI Joins ExCell Research Study Using Stem Cells For Leukemia And Lymphoma Patients
The University of Pittsburgh Cancer Institute (UPCI) and the Gamida Cell - Teva Joint Venture announced today that the Institute has joined an elite group of cancer centers in Europe, the United States and Israel that are now enrolling patients to participate in the ExCell research study.
News of the day
Federal Appeals Court Upholds Virginia Abortion Ban
The full U.S. Court of Appeals for the 4th Circuit in a 6-5 decision on Wednesday upheld Virginia"s 2003 law banning what abortion-rights opponents call "partial-birth" abortion, a procedure known medically as intact dilation and extraction, the AP/Hartford Courant reports (O"Dell, AP/Hartford Courant, 6/24). In 2005, a three-judge panel of the U.S. Court of Appeals for the 4th Circuit ruled 2-1 to strike down the Virginia law on the grounds that it does not include adequate exceptions to protect a woman"s health. The U.S. Supreme Court two years ago ordered the appeals court to revisit the issue when it upheld the Partial Birth Abortion Ban Act of 2003, a federal law similar to the Virginia law (White, Washington Post, 6/25). The three-judge appeals panel again struck down the law in 2008 (AP/Hartford Courant, 6/24). The Virginia law permits women to choose various abortion procedures but makes it a crime for providers to perform an intact dilation and extraction, which involves crushing a fetus" skull to ease removal (Washington Post, 6/25). Abortion-rights supporters said that the Virginia law is unconstitutional because its broad definition of intact dilation and extraction could also prohibit standard dilation and extraction, the more common form of second-trimester abortion. Violations of the law would be considered a felony and punishable by up to 10 years in prison. The case is Richmond Medical Center v. Herring (AP/Hartford Courant, 6/24). William Fitzhugh, the Richmond doctor who challenged the Virginia law, said that the banned procedure is necessary to protect the life of the woman in some cases and that the law could prevent abortion providers from performing legal procedures out of fear of prosecution. Stephanie Toti, a Center for Reproductive Rights attorney who represented the plaintiffs, said that the Virginia law is broader than federal law because it punishes abortion providers who accidentally violate the law while performing legal abortion procedures. Judge"s Opinions Judge Paul Niemeyer in the majority opinion wrote that Virginia law protects physicians who are taking needed steps to save a patient"s life and should prevent "a Morton"s fork, where the doctor must choose between criminal liability or care that the doctor believes is not in the best interest of the patient." He added that the circumstances in which doctors could face criminal liability are so limited that they should not invalidate the law in every other case. Judge Blane Michael wrote in the dissenting opinion that the law will create a "real fear of criminal liability" among physicians because it will have the effect of criminalizing the actions of those who seek to perform legal procedures but need to use the banned procedure in rare instances. Michael wrote that the law therefore "places an undue burden on a woman"s right to obtain a pre-viability second trimester abortion -- a constitutional right repeatedly reaffirmed by the Supreme Court" (Washington Post, 6/25).Next StepsToti said that no decision has been made on whether to appeal the decision to the Supreme Court. The Supreme Court"s 2007 decision on the federal law made it clear that abortion bans must include exceptions for the health of the woman, the AP/Hartford Courant reports. Toti said that the appeals court"s decision "just really ignores that precedent." She added, "It"s really insulting to women"s dignity that the court would put so little priority on protecting women"s health and well-being" (AP/Hartford Courant, 6/25). Toti also said, "It puts doctors in a really untenable position because it forces doctors to choose between taking all the steps necessary to protect their patients and committing a felony" (Washington Post, 6/25). Virginia Attorney General Bill Mims said, "While we anticipate that the U.S. Supreme Court may be asked to review the decision, I am confident that the Supreme Court ultimately will uphold the law" (AP/Hartford Courant, 6/25).
Endocrinology

2009 Recipient Of Minority Scholar Award Begins Clinical Research On Leukemia

Alejandro Gutierrez, MD, is the third recipient of the ASH-AMFDP grant, an award designed to help increase the number of underrepresented minority scholars in the field of hematology, and will begin his research into the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL) this month. The award, the result of a partnership between the American Society of Hematology (ASH) and the Harold Amos Medical Faculty Development Program (AMFDP) of the Robert Wood Johnson Foundation, provides four years of support, including an annual stipend of up to $75,000 and an annual grant of more than $29,000 for research activities. "I am truly honored to have been selected as the 2009 recipient of the ASH-AMFDP," said Dr. Gutierrez. "This award represents an outstanding career development opportunity for which I am most grateful, and I look forward to years of productive collaboration with ASH and the AMFDP." His research is entitled "Unraveling the Molecular Pathogenesis of T-Cell Acute Lymphoblastic Leukemia Using Zebrafish Genetics and Small Molecule Screens," and will focus on harnessing the strengths of the zebrafish model system to unravel the molecular pathogenesis of T-cell acute lymphoblastic leukemia. Specifically, Dr. Gutierrez is interested in identifying targetable molecular pathways that are required for the survival of MYC-overexpressing thymocytes using a zebrafish small molecule screen, and in uncovering the functional roles of novel T-ALL oncogenes and tumor suppressors in our zebrafish model of this disease. Dr. Gutierrez is currently Instructor in Pediatrics, Dana-Farber Cancer Institute, Children"s Hospital Boston, Harvard Medical School. For more information, please see the ASH-AMFDP page on the ASH Web site. The American Society of Hematology is the world"s largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology. In September, ASH launched Blood: The Vital Connection , a credible online re addressing bleeding and clotting disorders, anemia, and cancer. It provides hematologist-approved information about these common blood conditions including risk factors, preventive measures, and treatment options. The American Society of Hematology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):